A potential new malaria vaccine has shown promise in animal studies, according to research. An Oxford University team is to start safety trials in human volunteers after lab tests showed the vaccine works against all strains of the parasite. UK scientists recently found the route malaria uses to enter blood cells. They hope to target this pathway in a new approach to developing a vaccine against malaria, which kills hundreds of thousands of people a year. Several potential malaria vaccines are already being tested in clinical trials; although no vaccine has yet been licensed for use. Early clinical trials in Africa suggest a vaccine known as RTS,S appears to protect about half of people vaccinated from malaria. While these results are encouraging, some scientists believe a more effective vaccine is needed to fight the disease. One possibility is to exploit a recently-discovered potential weakness in the parasite's life cycle. A team at the Sanger Institute found in November that a single receptor on the surface of red blood cells and a substance known as "PfRh5" on the parasite are crucial to the success of malaria in invading blood cells. Early lab tests suggest a vaccine against the protein may prove effective, at least in animals. Dr Sandy Douglas is a Wellcome Trust Clinical Research Training Fellow from the University of Oxford and first author on the study, published in the journal, Nature Communications. He told the BBC: "We have found a way of making antibodies that kill all different strains of malaria parasites. This is still early phase research in animals. The next step is to do clinical trials in people." If safety tests of the vaccine prove successful, clinical trials in patients could begin within the next two to three years, says the Oxford team. Dr Gavin Wright, from the Wellcome Trust Sanger Institute, said recent findings on how the malaria parasite invades red blood cells were unexpected. Dr Wright, a co-author on both studies, added: "It revealed what we think is the parasite's Achilles heel in the way it invades our cells and provided a target for potential new vaccines."
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor